CD19 and diffuse large B-cell lymphoma: Tafasitamab is an FDA-approved humanized monoclonal antibody targeting the pan B-cell antigen CD19 and used in the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) [16].